Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions / Catheter Cardiovasc Interv. 2021 Nov 15;98(6):E908-E917. doi: 10.1002/ccd.29807. Epub 2021 Jun 12.
2021
AO Ordine Mauriziano
Tipo pubblicazione
Journal Article
Autori/Collaboratori (35)Vedi tutti...
Mehran R
Department of Cardiology, IRCCS San Raffael Hospital, Segrate, Italy.
Morice MC
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Chieffo A
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
et alii...
Abstract
OBJECTIVES: To describe the incidence, predictors, and clinical impact of permanent pacemaker insertion (PPI) following transcatheter aortic valve replacement (TAVR) in women. BACKGROUND: Data on pacemaker insertion complicating TAVR in women are scarce. METHODS: The Women's International Transcatheter Aortic Valve implantation (WIN-TAVI) is a prospective registry evaluating the safety and efficacy of TAVR in women. We included patients without preprocedural pacemakers and divided them into two groups: (1) PPI and (2) no-PPI. We identified PPI predictors using logistic regression and studied its clinical impact on the Valve Academic Research Consortium (VARC)-2 efficacy and safety endpoints. RESULTS: Out of 1019 patients, 922 were included in the analysis. Post-TAVR PPI occurred in 132 (14.3%) patients. Clinical and procedural characteristics were similar in both groups. Pre-existing right bundle branch block (RBBB) was associated with a high risk of post-TAVR PPI (OR 3.62, 95% CI 1.85-7.06, p?0.001), while implantation of balloon-expandable prosthesis was associated with a lower risk (OR 0.47, 95% CI 0.30-0.74, p?0.001). Post-TAVR PPI prolonged in-hospital stay by a median of 2?days (11 [9-16] days in PPI vs. 9 [7-14] days in no-PPI, p = 0.005), yet risks of VARC-2 efficacy and safety endpoints at 1?year were similar in both groups ((adj) HR 0.95, 95% CI 0.60-1.52, p = 0.84 and (adj) HR 1.22, 95% CI 0.83-1.79, p = 0.31, respectively). CONCLUSION: Pacemaker implantation following TAVR is frequent among women and is associated with pre-existing RBBB and valve type. PPI prolongs hospital stay, albeit without any significant impact on 1-year outcomes.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 34117817
DOI : 10.1002/ccd.29807
Keywords
TAVI; TAVR; Treatment Outcome; Transcatheter Aortic Valve Replacement/adverse effects; Risk Factors; Registries; Pacemaker, Artificial; Humans; Incidence; Female; Aortic Valve Stenosis/diagnostic imaging/surgery; pacemaker; gender; Aortic Valve/diagnostic imaging/surgery;